Thompson Wesley K, Kupfer David J, Fagiolini Andrea, Scott John A, Frank Ellen
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15260, USA.
J Clin Psychiatry. 2006 May;67(5):783-8. doi: 10.4088/jcp.v67n0512.
We studied the relationship between number of medical comorbidities in patients with bipolar I disorder and their demographic and clinical characteristics.
Data were from 174 patients in the acute phase of the Pittsburgh Maintenance Therapies in Bipolar Disorder (MTBD) study, a randomized controlled trial comparing Interpersonal and Social Rhythm Therapy to an intensive clinical management approach for individuals with a lifetime diagnosis of bipolar I disorder or schizoaffective disorder, manic type, according to Research Diagnostic Criteria, who were receiving adjunctive protocol-driven pharmacotherapy. Patients entered the MTBD study from 1991 to 2000. We examined the acute-phase Hamilton Rating Scale for Depression (HAM-D) and Bech-Rafaelsen Mania Scale scores, demographics, clinical history, and medical comorbidities.
Patients with a high number of medical comorbidities had longer duration of both lifetime depression (p = .02) and lifetime inpatient depression treatment (p = .04), had higher baseline HAM-D score (p = .01), and were more likely to be treated for a depressed clinical state during the acute phase of the MTBD study (p = .05). Moreover, higher severity of baseline medical comorbidities predicted slower decreases in HAM-D score among depressed (p = .004) and mixed/cycling (p = .003) patients even after controlling for baseline HAM-D score.
Medical illness is correlated with several indicators of poorer prognosis and outcome in bipolar I disorder. Not only do preventing and treating medical comorbidities in bipolar patients decrease the morbidity and mortality related to physical illness, but they could also enhance psychological well-being and possibly improve the course of bipolar illness. Identification of characteristics in bipolar I patients that are correlated to increased risk for medical comorbidities is a fundamental step in understanding the nature of the relationship between bipolar disorder and medical illness.
我们研究了双相I型障碍患者的医学共病数量与其人口统计学和临床特征之间的关系。
数据来自双相情感障碍匹兹堡维持治疗(MTBD)研究急性期的174名患者,该研究是一项随机对照试验,根据研究诊断标准,将人际和社会节律疗法与强化临床管理方法进行比较,对象为终生诊断为双相I型障碍或精神分裂症性障碍(躁狂型)且正在接受辅助方案驱动药物治疗的个体。患者于1991年至2000年进入MTBD研究。我们检查了急性期汉密尔顿抑郁评定量表(HAM-D)和贝奇-拉法尔森躁狂量表得分、人口统计学、临床病史和医学共病情况。
医学共病数量多的患者终生抑郁持续时间更长(p = 0.02),终生住院抑郁治疗时间更长(p = 0.04),基线HAM-D得分更高(p = 0.01),并且在MTBD研究急性期更有可能因抑郁临床状态接受治疗(p = 0.05)。此外,即使在控制了基线HAM-D得分之后,基线医学共病的更高严重程度仍预示着抑郁(p = 0.004)和混合/循环发作(p = 0.003)患者的HAM-D得分下降更慢。
躯体疾病与双相I型障碍预后和结局较差的几个指标相关。在双相情感障碍患者中预防和治疗医学共病不仅可以降低与躯体疾病相关的发病率和死亡率,还可以增强心理健康,并可能改善双相情感障碍的病程。识别双相I型患者中与医学共病风险增加相关的特征是理解双相情感障碍与躯体疾病之间关系本质的基本步骤。